However, there is a need to continuously evaluate IgG, IgA, and IgM antibodies against S, N, and RBD within different patient populations to provide a better understanding of COVID-19 as well as to assess the duration and the extent of antibody responses to natural infection. This evidence concerns the gene CD40LG and infection.